Business
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response against pat
About this update from Ac Immune Sa
[{"type":"image","alt":"AC Immune SA","displaySize":"","headline":null,"caption":"AC Immune SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":240,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ppRSnZQxE6Y9H9qhIOFsHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606","width":240,"height":75}},"lazy":false},{"type":"text","content":"Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine ","length":119,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s disease","length":259,"tagName":"p"}]},{"val":[{"type":"text","content":"ACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response against pathological forms of Tau after first dose","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"No clinically relevant safety and tolerability observations were reported","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"ACI-35.030 (JNJ-64042056) selected to advance and now in ongoing potentially registration-enabling Phase 2b ReTain clinical trial in preclinical Alzheimer’s disease","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":656,"olType":false},{"type":"text","content":"Lausanne, Switzerland, 25, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the peer-reviewed publication in eBioMedicine of results from the completed Phase 1b/2a trial of active immunotherapy ACI-35.030’s (JNJ-2056) partnered with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company. ACI-35.030 generated a rapid, robust and durable polyclonal response against pathological forms of Tau including phosphorylated Tau (pTau) and brain-derived Tau (enriched paired helical filament, ePHF). There were no clinically relevant safety or tolerability ob...